As Enveda Biosciences is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Enveda Biosciences, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
How to buy Enveda Biosciences stock?
To invest in a private company like Enveda Biosciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
Can you sell Enveda Biosciences stock?
Yes, you may sell the Enveda Biosciences stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
How to sell Enveda Biosciences stock?
If you hold private company shares of Enveda Biosciences – whether as an employee or an early investor – Forge can help you sell them.
Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Enveda Biosciences on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
To learn more about Enveda Biosciences stock
Is Enveda Biosciences a public company?
No, Enveda Biosciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
What is Enveda Biosciences’ stock price?
Enveda Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Enveda Biosciences private market stock price with Forge Data.
What is Enveda Biosciences’ stock ticker symbol?
Enveda Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Enveda Biosciences funding rounds and valuation
Total funding $346.14MM
Funding history chart
Funding round details
Funding Date
Share Class
Amount Raised
Price Per Share
Post-Money Valuation 3
Key Investors
02/27/2025
Series C
$150MM
$5.27
$648.97MM
Baillie Gifford, Cresset Partners, Dimension Capital, Fpv, Henry R. Kravis, Kinnevik, Lingotto, Lux Capital, Premji Invest, Sanofi, The Nature Conservancy, True Ventures
Price Per Share
$5.27
Shares Outstanding
28,439,254
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Baillie Gifford, Cresset Partners, Dimension Capital, Fpv, Henry R. Kravis, Kinnevik, Lingotto, Lux Capital, Premji Invest, Sanofi, The Nature Conservancy, True Ventures
06/14/2024
Series B+
$65.69MM
$4.65
$377.48MM
Dimension Capital, Fpv, Henry R. Kravis, Kinnevik, True Ventures, Wireframe Ventures
Price Per Share
$4.65
Shares Outstanding
14,132,527
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Dimension Capital, Fpv, Henry R. Kravis, Kinnevik, True Ventures, Wireframe Ventures
04/20/2023
Series B
$74.31MM
$3.94
$258.89MM
Allen & Company, Amino Collective, Dimension Capital, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
Price Per Share
$3.94
Shares Outstanding
18,860,406
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Amino Collective, Dimension Capital, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
04/20/2023
Series B-1
$21MM
$3.15
$258.89MM
Allen & Company, Amino Collective, Dimension Capital, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
Price Per Share
$3.15
Shares Outstanding
6,662,266
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Amino Collective, Dimension Capital, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
06/22/2021
Series A
$30.16MM
$2.80
$95.67MM
Catalio Capital, Chris Gibson, Hummingbird Ventures, Lifeforce Capital, Lux Capital, True Ventures, Two Sigma Ventures, Village Global, Wireframe Ventures
Price Per Share
$2.80
Shares Outstanding
10,755,620
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital, Chris Gibson, Hummingbird Ventures, Lifeforce Capital, Lux Capital, True Ventures, Two Sigma Ventures, Village Global, Wireframe Ventures
12/27/2020
Series Seed
$4.1MM
$0.59
$12.77MM
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price Per Share
$0.59
Shares Outstanding
6,932,114
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020
Series Seed-1
$304,331.88
$0.46
$12.77MM
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price Per Share
$0.46
Shares Outstanding
662,888
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020
Series Seed-2
$145,003.08
$0.44
$12.77MM
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price Per Share
$0.44
Shares Outstanding
326,878
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020
Series Seed-3
$225,023.89
$0.38
$12.77MM
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price Per Share
$0.38
Shares Outstanding
588,144
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020
Series Seed-4
$56,759.77
$0.19
$12.77MM
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price Per Share
$0.19
Shares Outstanding
291,824
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020
Series Seed-5
$150,042.94
$0.16
$12.77MM
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price Per Share
$0.16
Shares Outstanding
914,896
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Company details
Enveda Biosciences is a drug discovery platform focusing on natural biological activity as a means of development. Their current pipeline includes pain and topical dermatology areas. Enveda Biosciences was founded in 2019 by Viswa Colluru Ph.D. and Pieter Dorrestein and is headquartered in Boulder, CO.
Enveda Biosciences Inc., a biotechnology company that leverages artificial intelligence to develop new medicines, announced that it has raised $130 million in new funding.
Since its launch in 2019, Enveda Biosciences has raised $124 million to advance its pipeline of nature-based small molecules targeting difficult therapeutic problems, most recently closing a Series B round in the midst of a stingy financing environment.
Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the company’s Chief Medical Officer. Dr. Deeg is a medical and pharmaceutical leader with broad experience developing drugs and digital therapeutics at companies from biopharma startups to pharmaceutical giants like Eli Lilly & Co., where he spent more than a decade.
Forge is your trusted partner to buy and sell Enveda Biosciences stock
Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
Most active companies are companies with a high market activity with the highest post-money valuation in the same sector.
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
July Private Market Update
